Skip to main content

Table 3 Clinical studies for biomarkers under investigation for diagnosis of NSCLC

From: Clinical potential of gene mutations in lung cancer

Study name Identifiera Purpose Biomarker(s)
Detection and diagnosis of NSCLC
 Prospective blinded evaluation of salivary transcriptome biomarkers for NSCLC detection NCT02294578 Evaluate sensitivity and specificity of biomarkers (mRNA) from saliva of patients with lung lesions prior to cancer diagnosis BRAF, CCNI, EGFR, FGF19, FRS2, GREB1, and LZTS1
 Molecular Diagnosis on circulating tumor DNA of NSCLC (ANTiCIPe) NCT02169349 Develop an assay to detect DNA mutation in circulating tumor DNA (from plasma) for diagnosis, treatment, and monitoring cancer progression of NSCLC (stage IIIb and IV) N/S
  1. N/S biomarkers were not specified, BRAF v-raf murine sarcoma viral oncogene homolog B1, CCN1 cycline I, EGFR epidermal growth factor receptor, FGF19 fibroblast growth factor 19, FRS2 fibroblast growth factor receptor substrate 2, GREB1 growth regulation by estrogen in breast cancer 1, LZTS1 leucine zipper, putative tumor suppressor 1
  2. aDenotes http://www.clinicaltrials.gov identifier